Propranolol and Semax Interaction: Monitor | Peptide Database

The most common nootropic use case for 9-Me-BC is the restoration of dopaminergic function following periods of stimulant use (amphetamines, methylphenidate, high-dose caffeine) that may have downregulated dopamine receptors or depleted dopaminergic tone. By upregulating TH and promoting dopaminergic neuron health, 9-Me-BC theoretically supports the recovery of normal motivational drive and reward sensitivity. Evidence is limited to animal models and user reports. Used in the bodybuilding and performance-enhancement community during PCT (post-cycle therapy) phases following SARM or prohormone cycles, where hormonal suppression can reduce dopaminergic tone. The rationale is to support neurological recovery alongside endocrine recovery. 9-Me-BC has been studied in animal models of Parkinson's disease, where it demonstrated the ability to restore dopaminergic neuron function and promote neurite regrowth in lesioned dopaminergic pathways. These findings are promising but remain preclinical, with no human trials conducted. The combination of TH upregulation, neurotrophic activity, and anti-neuroinflammatory effects positions 9-Me-BC as a potentially broad neuroprotective agent for the dopaminergic system. However, the phototoxicity risk and lack of human data significantly complicate any long-term neuroprotective application. Through enhanced dopamine synthesis capacity, users report improvements in baseline motivation, initiative, and the ability to engage in cognitively demanding tasks. Effects are described as subtle and cumulative rather than acutely stimulating.

First-line pharmacotherapy for ED of various etiologies. Demonstrated efficacy across a broad range of populations including patients with diabetes, spinal cord injury, post-radical prostatectomy, and psychogenic ED. Effective in approximately 70-85% of men with ED. Rapid onset and predictable duration make sildenafil well-suited for planned sexual activity. The shorter therapeutic window provides a defined period of enhanced erectile response without prolonged pharmacological effect. FDA-approved as Revatio (20mg TID) for PAH (WHO Group 1) to improve exercise capacity and delay clinical worsening. Reduces mean pulmonary artery pressure, pulmonary vascular resistance, and improves 6-minute walk distance. Evidence from controlled trials demonstrates that sildenafil reduces the frequency and severity of Raynaud's attacks by enhancing digital blood flow through NO-cGMP pathway augmentation. Used off-label in refractory cases. Acute and chronic PDE5 inhibition with sildenafil improves flow-mediated dilation and endothelial-dependent vasodilation across various cardiovascular risk populations. Sildenafil has been studied for the prevention and treatment of high-altitude pulmonary edema (HAPE) by reducing exaggerated hypoxic pulmonary vasoconstriction. Used off-label by climbers and military personnel at extreme altitudes. Used off-label in neonatal ICUs for persistent pulmonary hypertension of the newborn (PPHN) when inhaled nitric oxide is unavailable or insufficient. Evidence supports its use as an adjunct therapy. Enhanced vasodilation may increase blood flow to working muscles. Some evidence suggests improved exercise performance at altitude via reduced pulmonary artery pressure. Effects at sea level are less well-established.